Reply to:‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’by D. Fabrizio et al.

摘要: (A, B) ICB response rates in (A) category I and (B) category II cancers, stratified by revised TMB including exclusion of driver mutations. Error bars indicate 95% confidence interval. The shaded region indicates 95% confidence interval for the KEYNOTE-158 response rate. Odds ratio and significance determined by the Cochrane ManteleHaenszel method between TMB-L and TMB-H. PRR> 20% indicates binomial P value evaluating if the response rate is> 20%. PRR< KN158 indicates if the response rate is less than that observed in the KEYNOTE-158 trial by Fisher’s exact test.(C) Analysis of odds ratio for ICB response per (B) at varying thresholds for TMB-H.(DF) Difference in percentage of tumors identified as TMB-H, where each pair of dots indicates a different cancer type, between (D) Foundation Medicine dataset (FMI) from Fabrizio et al. 1 and the analyzed ICB-treated cohorts;(E) FMI and TCGA cohorts …